REPLIGEN CORP Insider Trading for March 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REPLIGEN CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REPLIGEN CORP for March 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 96.72 | 1,858 | 179,706 | 923 | 2.8 K to 923 (-66.81 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 42.07 | 3,304 | 138,999 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 38.76 | 2,434 | 94,342 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 26.12 | 3,366 | 87,920 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 41.19 | 3,632 | 149,602 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 12.91 | 14,000 | 180,740 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 97.17 | 1,016 | 98,725 | 2,781 | 3.8 K to 2.8 K (-26.76 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 96.45 | 1,187 | 114,486 | 3,797 | 5 K to 3.8 K (-23.82 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 95.13 | 24,533 | 2,333,824 | 4,984 | 29.5 K to 5 K (-83.11 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 42.07 | 3,304 | 138,999 | 29,517 | 26.2 K to 29.5 K (+12.60 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 38.76 | 2,434 | 94,342 | 26,213 | 23.8 K to 26.2 K (+10.24 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 26.12 | 3,366 | 87,920 | 23,779 | 20.4 K to 23.8 K (+16.49 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 41.19 | 3,632 | 149,602 | 20,413 | 16.8 K to 20.4 K (+21.64 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 12.91 | 14,000 | 180,740 | 16,781 | 2.8 K to 16.8 K (+503.42 %) |
| Mar 18 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | M | 42.07 | 500 | 21,035 | 0 | |
| Mar 18 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | M | 38.76 | 500 | 19,380 | 1,934 | |
| Mar 18 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 91.48 | 1,000 | 91,480 | 1,923 | 2.9 K to 1.9 K (-34.21 %) |
| Mar 18 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 42.07 | 500 | 21,035 | 2,923 | 2.4 K to 2.9 K (+20.64 %) |
| Mar 18 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 38.76 | 500 | 19,380 | 2,423 | 1.9 K to 2.4 K (+26.00 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 90.39 | 1,045 | 94,458 | 36,127 | 37.2 K to 36.1 K (-2.81 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 88.18 | 610 | 53,790 | 37,172 | 37.8 K to 37.2 K (-1.61 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | M | 42.07 | 2,804 | 117,964 | 500 | |
| Mar 05 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | M | 41.19 | 1,992 | 82,050 | 0 | |
| Mar 05 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 88.82 | 4,796 | 425,981 | 1,923 | 6.7 K to 1.9 K (-71.38 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 42.07 | 2,804 | 117,964 | 6,719 | 3.9 K to 6.7 K (+71.62 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 41.19 | 1,992 | 82,050 | 3,915 | 1.9 K to 3.9 K (+103.59 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 85.72 | 2,225 | 190,727 | 1,923 | 4.1 K to 1.9 K (-53.64 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 90.99 | 1,905 | 173,336 | 26,524 | 28.4 K to 26.5 K (-6.70 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 90.08 | 650 | 58,552 | 28,429 | 29.1 K to 28.4 K (-2.24 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 88.35 | 450 | 39,758 | 29,079 | 29.5 K to 29.1 K (-1.52 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 12.91 | 10,000 | 129,100 | 14,000 | |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 93.39 | 10,000 | 933,900 | 2,781 | 12.8 K to 2.8 K (-78.24 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 12.91 | 10,000 | 129,100 | 12,781 | 2.8 K to 12.8 K (+359.58 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 90.13 | 12,300 | 1,108,599 | 230,241 | 242.5 K to 230.2 K (-5.07 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 88.56 | 100 | 8,856 | 242,541 | 242.6 K to 242.5 K (-0.04 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 88.20 | 2,090 | 184,338 | 242,641 | 244.7 K to 242.6 K (-0.85 %) |
| Mar 02 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Option Exercise | A | 44.13 | 4,571 | 201,718 | 4,571 | |
| Mar 02 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Grant | A | 0.00 | 4,686 | 0 | 37,782 | 33.1 K to 37.8 K (+14.16 %) |
| Mar 02 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Option Exercise | A | 86.10 | 18,128 | 1,560,821 | 18,128 | |
| Mar 02 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Grant | A | 0.00 | 18,583 | 0 | 244,731 | 226.1 K to 244.7 K (+8.22 %) |
| Mar 02 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | A | 86.10 | 3,137 | 270,096 | 3,137 | |
| Mar 02 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Grant | A | 0.00 | 3,216 | 0 | 29,529 | 26.3 K to 29.5 K (+12.22 %) |